在治疗中,微生物群和脑肠轴之间的相互作用
Hanxiao Zhu1,2, Wei Wang3, Yun Li1,2
1Department of Neurology, The First Affiliated Hospital of Dali University, Dali, China.
Frontiers in pharmacology
|February 12, 2024
概括
肠道微生物群对有影响. 像性饮食这样的干预措施可以通过向大脑-肠轴来帮助管理耐药性,尽管需要更多的研究.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 大脑-肠轴连接大脑功能和肠道健康.
- 微生物群失衡与,阿尔茨海默氏症和帕金森病等神经系统疾病有关.
研究的目的:
- 审查关于肠道微生物群在中的作用的临床和动物证据.
- 探索大脑-肠轴路径受肠道微生物群在中的影响.
- 讨论针对微生物群的治疗方法.
主要方法:
- 临床和动物研究的文献综述.
- 对的肠道微生物群干预措施的证据分析.
- 检查大脑-肠轴机制.
主要成果:
- 肠道微生物群的干扰可能会导致的进展和耐药性.
- 诸如便微生物群移植和性饮食等干预措施对有希望.
- 建议肠道微生物群对抗药物的疗效和副作用的影响.
结论:
- 肠道微生物群调节是的潜在治疗策略.
- 需要进一步的研究,以充分阐明微生物群的作用和优化治疗方法.
- 性饮食和便微生物群移植是治疗的有希望的途径.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
402
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
402
Antiepileptic Drugs: Glutamate Antagonists
357
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
357
Arteries of the Lower Limbs
190
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
190
Antiepileptic Drugs: Potassium Channel Activators
183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
183
Irritable Bowel Syndrome I: Introduction
275
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
275
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
302
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
302


